National Working Group Meeting on ALK diagnostics in lung cancer

Cooper, Wendy, Fox, Stephen, O'Toole, Sandra, Morey, Adrienne, Frances, Glenn, Pavlakis, Nick, O'Byrne, Kenneth, Dettrick, Andrew, Leong, Trishe, Rathi, Vivek, Spagnolo, Dominic, Hemmings, Chris, Singh, Mahendra, Moffat, David, Tsao, Ming-Sound, Wilner, Keith, Buller, Richard, Pitman Lowenthal, Susan, Arifeen, Shams, Binko, Justin and Alam, Mahmood (2014) National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10 Supp. 2: 11-17. doi:10.1111/ajco.12190


Author Cooper, Wendy
Fox, Stephen
O'Toole, Sandra
Morey, Adrienne
Frances, Glenn
Pavlakis, Nick
O'Byrne, Kenneth
Dettrick, Andrew
Leong, Trishe
Rathi, Vivek
Spagnolo, Dominic
Hemmings, Chris
Singh, Mahendra
Moffat, David
Tsao, Ming-Sound
Wilner, Keith
Buller, Richard
Pitman Lowenthal, Susan
Arifeen, Shams
Binko, Justin
Alam, Mahmood
Title National Working Group Meeting on ALK diagnostics in lung cancer
Journal name Asia-Pacific Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1743-7555
1743-7563
Publication date 2014-04
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/ajco.12190
Open Access Status
Volume 10
Issue Supp. 2
Start page 11
End page 17
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell
Collection year 2015
Language eng
Subject 2730 Oncology
Formatted abstract
The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.
Keyword ALK testing
Fluorescence in situ hybridization
Immunohistochemistry
Molecular diagnostics
Nonsmall cell lung cancer
Q-Index Code CX
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Non HERDC
Official Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 15 Apr 2014, 01:23:15 EST by System User on behalf of School of Medicine